Follow-up study for men previously treated with CSL222
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study checks long-term safety and outcomes in men with hemophilia B who previously received CSL222. It may help your care team better understand how well the treatment lasts over many years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received CSL222 (etranacogene dezaparvovec) in the earlier CSL222 studies (CSL222_2001 or CSL222_3001).
- You must have already completed one of those earlier studies, or at least 5 years must have passed since your CSL222 dose.
- You are enrolling as a male adult (adult age group).
- This is a follow-up study only—there are no other listed exclusion rules for eligibility here.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called CSL222 for adults with hemophilia B who have antibodies against the AAV5 virus used to deliver the therapy. It aims to see if the treatment is safe and effective even when these antibodies are present.
This trial tests a single dose of CSL222, a gene therapy, in adolescent boys with severe or moderately severe hemophilia B. The goal is to see if it can reduce or eliminate the need for regular factor IX infusions.
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
Hear when a new Hemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.